On identifying instances of novel FDA-approved drug repositioning for sensitization of P-gp-overexpressing-resistant cancers, we speculate that these drugs could be administered to patients with MDR cancer without warranting additional toxicity testing. This evidence concerns the gene PGP and cancer.